logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

    Article - En anglais

    Objective 

    To estimate the cost-effectiveness of interferon-alpha2B for the treatment of patients with chronic hepatitis B infection who are positive for hepatitis B e antigen (HBeAg).

    Design 

    Meta-analysis of nine randomized controlled trials and cost-effectiveness analysis, projecting the clinical and economic outcomes expected from changes in serologic markers of hepatitis B viral replication.

    Data Sources 

    MEDLINE search, expert panel opinion, hospital cost data, and adjusted physician charges.

    Patients 

    552 patients with confirmed chronic hepatitis B infection who were positive for HBeAg.

    Intervention 

    Interferon-alpha2b.

    Results 

    Interferon-alpha2b increases the likelihood of becoming negative for HBeAg from 9.1% to 45.6% (difference, 36.5% ; 95% CI, 23.7% to 49.2%) and of becoming negative for hepatitis B surface antigen from 1.7% to 7.7% (difference, 6.0% ; CI, 2.8% to 9.3%) in the first year.

    For a 35-year-old person with chronic hepatitis B who is HBeAg positive, our analysis suggests that interferon-alpha2b will increase life expectancy by 3.1 years or 3.4 quality-adjusted life-years and will decrease projected lifetime costs, even if future savings are discounted.

    Even with the model biased strongly in favor of standard care, the marginal cost-effectiveness ratio of interferon did not exceed $12 000 per life-year gained.

    Conclusions 

    Interferon-alpha2b should prolong life and lower costs for patients with chronic hepatitis B who are HBeAg positive.

    Mots-clés Pascal : Hépatite virale B, Virose, Infection, Chronique, Interféron alpha, Coût, Chimiothérapie, Traitement, Homme, Economie santé, Antigène HBe, Appareil digestif pathologie, Foie pathologie, Cytokine

    Mots-clés Pascal anglais : Viral hepatitis B, Viral disease, Infection, Chronic, Alpha interferon, Costs, Chemotherapy, Treatment, Human, Health economy, Hepatitis B e antigen, Digestive diseases, Hepatic disease, Cytokine

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0328076

    Code Inist : 002B02Q. Création : 01/03/1996.